Melphalan 200 mg/m 2 versus Melphalan 100 mg/m 2 in newly diagnosed myeloma patients: a prospective, multi-center phase III study.
Autori:
Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I , Cavallo F, Petrucci MT, Massaia M, Boccadoro M.
Rivista:
Blood 2010; 115: 1873-9.